- Home
- MGRX vs IMRN Comparison
MGRX vs IMRN Comparison
Compare MGRX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- IMRN
- Stock Information
- Founded
- MGRX 2021
- IMRN 1994
- Country
- MGRX United States
- IMRN Australia
- Employees
- MGRX N/A
- IMRN N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- IMRN Health Care
- Exchange
- MGRX Nasdaq
- IMRN Nasdaq
- Market Cap
- MGRX 8.1M
- IMRN 9.2M
- IPO Year
- MGRX 2023
- IMRN N/A
- Fundamental
- Price
- MGRX $2.04
- IMRN $1.70
- Analyst Decision
- MGRX
- IMRN Strong Buy
- Analyst Count
- MGRX 0
- IMRN 1
- Target Price
- MGRX N/A
- IMRN $5.00
- AVG Volume (30 Days)
- MGRX 202.3K
- IMRN 53.0K
- Earning Date
- MGRX 05-15-2025
- IMRN 06-17-2025
- Dividend Yield
- MGRX N/A
- IMRN N/A
- EPS Growth
- MGRX N/A
- IMRN N/A
- EPS
- MGRX N/A
- IMRN N/A
- Revenue
- MGRX $511,084.00
- IMRN $4,048,286.00
- Revenue This Year
- MGRX N/A
- IMRN N/A
- Revenue Next Year
- MGRX N/A
- IMRN N/A
- P/E Ratio
- MGRX N/A
- IMRN N/A
- Revenue Growth
- MGRX N/A
- IMRN 82.90
- 52 Week Low
- MGRX $1.32
- IMRN $1.50
- 52 Week High
- MGRX $7.66
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- MGRX 52.44
- IMRN 43.37
- Support Level
- MGRX $2.05
- IMRN $1.69
- Resistance Level
- MGRX $2.28
- IMRN $1.89
- Average True Range (ATR)
- MGRX 0.24
- IMRN 0.17
- MACD
- MGRX 0.06
- IMRN -0.01
- Stochastic Oscillator
- MGRX 57.56
- IMRN 34.06
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.